Atossa Genetics Reports 47% Surge in Short Interest in December

Atossa Genetics Inc. experienced a substantial increase in short interest in December, with the total reaching 2,284,050 shares as of December 15. This figure marks a notable growth of 47.0% from the previous month’s total of 1,554,063 shares recorded on November 30. The current days-to-cover ratio, based on an average daily trading volume of 1,461,615 shares, stands at 1.6 days. Approximately 1.9% of the company’s shares are currently sold short.

Analysts have recently provided their insights regarding Atossa Genetics’ stock. On December 8, Ascendiant Capital Markets raised their price target on the shares from $7.75 to $8.00, issuing a “buy” rating in their research note. Conversely, Zacks Research downgraded the shares from a “hold” rating to a “strong sell” rating on October 13. Weiss Ratings also reiterated a “sell (D-)” rating in a report published on October 8. Overall, one research analyst has assigned a Strong Buy rating, two have issued Buy ratings, and two have given Sell ratings to Atossa Genetics, leading to a consensus rating of “Hold” with an average target price of $6.33, according to data from MarketBeat.com.

Atossa Genetics Stock Performance and Financial Outlook

As of Wednesday, Atossa Genetics stock opened at $0.62, reflecting a decline of 5.6%. The company’s stock has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.83. Over the past year, the stock has seen a low of $0.55 and a high of $1.29. Atossa Genetics holds a market capitalization of $80.28 million, with a price-to-earnings ratio of -2.59 and a beta of 0.95.

In its most recent earnings report, released on November 12, Atossa Genetics reported earnings per share of ($0.07), matching analysts’ consensus estimates. Looking ahead, equities analysts predict that the company will post earnings of ($0.22) per share for the current fiscal year.

Company Overview and Strategic Focus

Atossa Genetics, based in Seattle, Washington, is a clinical-stage biotechnology company dedicated to developing therapeutics and diagnostic products for breast cancer and related conditions. The firm focuses on delivering targeted and minimally invasive solutions aimed at early detection, treatment, and prevention for women diagnosed with or at risk for breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those identified as high-risk for recurrence.

As Atossa Genetics continues to navigate market challenges and opportunities, stakeholder interest remains focused on its innovative approaches in the biotechnology sector.